Clinical and pharmacological group: & nbsp
Laxatives
Included in the formulation
АТХ:A.06.A.H.01 Methylnaltrexone bromide
Pharmacodynamics:Acts as a selective antagonist of peripheral opioid μ receptors (in the gastrointestinal tract), without affecting the analgesic effects of opioids in the central nervous system.
Has a central laxative effect, it retains efficacy up to 4 months of administration.
Pharmacokinetics:After subcutaneous administration, the maximum concentration in the blood plasma is reached after 30 minutes. The connection with plasma proteins is up to 15%.
Therapeutic effect develops after the reception. Metabolism in the liver to inactive metabolites.
The half-life is 8 hours. Elimination of the kidneys and feces, unchanged.
Indications:It is used to stimulate rapid defecation in the treatment of opioid-induced constipation, which patients receive oncological palliative care.
XI.K55-K63.K59.0 Constipation
Contraindications:Mechanical intestinal obstruction, severe renal and hepatic insufficiency, individual intolerance, children under 18 years of age.
Carefully:Patients with colostomy, fecal matter, active diverticulosis and intraperitoneal catheter.
Pregnancy and lactation:Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously, once a day, depending on the weight of the patient:
38-62 kg - 0.4 ml (8 mg);
62-114 kg - 0.6 ml (12 mg).
Side effects:Central and peripheral nervous system: dizziness.
Digestive system: gastralgia, nausea, flatulence.
Dermatological reactions: Hyperhidrosis.
Allergic reactions.
Overdose:Orthostatic hypotension.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:The drug does not cause addiction and drug dependence.
In the treatment it is not recommended to drive vehicles and work with moving mechanisms.